Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02096081 · ClinicalTrials.gov registry record · Phase 4
The Treatment of Glabellar Frown Lines
A Phase 4 study, sponsored by Merz North America.
- Completed
- Registry status
- Phase 4
- Development phase
- 250
- Enrollment target
NCT02096081: Completed Phase 4 study, sponsored by Merz North America.
NCT02096081 is a Phase 4 study that has completed, run by Merz North America. The registered enrollment target is 250 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02096081, a Phase 4 study, has completed, sponsored by Merz North America.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 250 participants
- Enrollment target
Study Summary
The purpose of this study is to show that two FDA-approved botulinum toxin drugs called Xeomin® and Botox® can reduce the severity of vertical lines (wrinkles) that appear between the eyebrows (glabellar frown lines).
Primary Outcome
Response defined as ≥ 1 point improvement from baseline (prior to treatment) on the Facial Wrinkle Scale at maximum frown as rated by an independent masked panel of physicians specifically qualified to assess study photographs using subject photographs at 1 month from treatment.
Interventions
- DRUG OnabotulinumtoxinA
- DRUG IncobotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-11 |
| Phase | Phase 4 |
What the finished NCT02096081 record still lists
NCT02096081 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 2 interventions - of which OnabotulinumtoxinA is the first listed.
NCT02096081 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02096081 about?
NCT02096081 is a clinical study titled "The Treatment of Glabellar Frown Lines". The purpose of this study is to show that two FDA-approved botulinum toxin drugs called Xeomin® and Botox® can reduce the severity of vertical lines (wrinkles) that appear between the eyebrows (glabellar frown lines).
What is the current status of trial NCT02096081?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 250 participants. The study started on 2014-02. Estimated completion is 2014-11.
What interventions are being tested in trial NCT02096081?
The interventions under investigation include: OnabotulinumtoxinA (DRUG), IncobotulinumtoxinA (DRUG).
Who is sponsoring clinical trial NCT02096081?
This trial is sponsored by Merz North America, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02096081's enrollment target sits among peer trials
250 342nd of 2000 higher than 1,648 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia